Piperaquine/dihydroartemisinin

Piperaquine/dihydroartemisinin (DHA/PPQ), sold under the brand name Eurartesim among others, is a fixed dose combination medication used in the treatment of malaria.[2] It is a combination of piperaquine and dihydroartemisinin.[2] Specifically it is used for malaria of the P. falciparum and P. vivax types.[3][4] It is taken by mouth.[3]

Piperaquine/dihydroartemisinin
Combination of
PiperaquineAntimalarial
DihydroartemisininAntimalarial
Clinical data
Trade namesDuoCotecxin, Artekin, Eurartesim, others
Other namesDihydroartemisinin/piperaquine phosphate
Routes of
administration
By mouth
Legal status
Legal status
  • UK: [1]
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
  • 497968-03-3

Side effects are uncommon.[4] Concerns include the possibility of QT prolongation.[4] Versions are available for use in children.[3] Use in early pregnancy is not recommended.[4] The two medications work by different mechanisms.[4]

Piperaquine/dihydroartemisinin was approved for medical use in Europe in 2011.[3] It is on the World Health Organization's List of Essential Medicines, the safest and most effective medicines needed in a health system.[2] While it was available for about US$6 per treatment course, efforts are underway as of 2010 to bring the price down one dollar per course.[4] It is commercially available in Africa and Asia.[3] It has been used to treat more than 4.5 million people as of 2017.[3]

PharmacologyEdit

Dihydroartemisinin (also known as dihydroqinghaosu, artenimol or DHA) is a drug used to treat malaria. Dihydroartemisinin is the active metabolite of all artemisinin compounds (artemisinin, artesunate, artemether, etc.) and is also available as a drug in itself. It is a semi-synthetic derivative of artemisinin and is widely used as an intermediate in the preparation of other artemisinin-derived antimalarial drugs.

Piperaquine is an antimalarial drug, a bisquinoline first made in the 1960s, and used extensively in China and Indochina as prophylaxis and treatment during the next 20 years. Usage declined in the 1980s as piperaquine-resistant strains of P. falciparum arose and artemisinin-based antimalarials became available. The combination dihydroartemisinin-piperaquine is an effective antimalarial that is used widely around the world. In South-East Asia, where resistance has emerged towards both artemisinin and piperaquine, the combination is being trialed with a third drug, namely mefloquine.[5]

Piperaquine is characterized by slow absorption and a long biological half-life, making it a good partner drug with artemisinin derivatives which are fast acting but have a short biological half-life.

Society and cultureEdit

This product is available in the market of several countries:

  • Artekin (Holleykin)
  • Eurartesim (Sigma Tau; by Good Manufacturing Practices)
  • Diphos (Genix Pharma)
  • Timequin (SAMI Pharma )
  • Duocotecxin (Holley Pharm)
  • Malacur (Elder Pharmaceuticals for SALVAT Laboratories)
  • Ridmal (Ajanta Pharma Limited)

ReferencesEdit

  1. ^ "Eurartesim 320 mg/40 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 10 April 2017. Retrieved 2 May 2020.
  2. ^ a b c World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  3. ^ a b c d e f "Eurartesim EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 3 May 2020.
  4. ^ a b c d e f "Dihydroartemisinin/Piperaquine Application for Inclusion in the 17th WHO Model List of Essential Medicines" (PDF). WHO. November 2010. Retrieved 29 June 2017. CS1 maint: discouraged parameter (link)
  5. ^ "TRAC II - Mahidol Oxford Tropical Medicine Research Unit". www.tropmedres.ac. Archived from the original on 28 July 2017. Retrieved 28 July 2017. CS1 maint: discouraged parameter (link)

External linksEdit